TMONYSEMeasuring & Controlling Devices, NECUS GAAP · USD

Thermo Fisher Scientific Inc

Thermo Fisher Scientific is a U.S.-based life sciences and laboratory company organized around four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It supplies instruments, consumables, diagnostics, and outsourced services used in research, clinical testing, and biopharmaceutical development and manufacturing across global markets.

Revenue44.6bn USD
+3.9 %y/y
Operating profit (EBIT)7,746m USD
+5.6 %y/y
EBIT margin17.4%
+0.3 ppy/y
Net income6,704m USD
+5.8 %y/y
Free cash flow6,293m USD
−13.4 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

01020304050bn USD2020: 32.2 bn USD2020: EBIT 7.8 bn USD20202021: 39.2 bn USD2021: EBIT 10.0 bn USD20212022: 44.9 bn USD2022: EBIT 8.4 bn USD20222023: 42.9 bn USD2023: EBIT 6.9 bn USD20232024: 42.9 bn USD2024: EBIT 7.3 bn USD20242025: 44.6 bn USD2025: EBIT 7.7 bn USD202544.67.7
RevenueOperating profit (EBIT)

Business

Share of revenue
Life Sciences Solutions25 %

Reagents, instruments, and workflow tools used in biological research and drug discovery.

Analytical Instruments20 %

Instrumentation and software for measuring, analyzing, and characterizing samples.

Specialty Diagnostics15 %

Diagnostic assays, instruments, and related products for clinical and applied testing.

Laboratory Products25 %

Consumables, chemicals, equipment, and procurement-channel offerings for labs.

Biopharma Services15 %

Outsourced development, clinical research, and manufacturing services for drug makers.

Products

Reported · share of revenue
41.9%41.7%16.4%FY2025100 %
  • Consumables41.9 %
  • Services41.7 %
  • Instruments16.4 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Thermo Fisher sells to pharmaceutical and biotechnology companies, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. It also serves industrial, environmental, and quality-control customers that need instruments, consumables, and testing services for regulated workflows. The company’s broad customer base reflects its role as a supplier of both mission-critical lab inputs and outsourced scientific services.

Pharmaceutical and biotechnology companies

Buy reagents, instruments, and outsourced development/manufacturing services to advance drug pipelines.

Clinical laboratories and hospitals

Buy diagnostic products and lab systems used in patient testing and clinical workflows.

Academic and government research

Buy research tools, consumables, and analytical systems for scientific programs.

Industrial and applied markets

Buy analytical and quality-control products for process monitoring and compliance.

Contract research and manufacturing customers

Buy integrated clinical research and pharma services for outsourced execution.

Strategy

Thermo Fisher’s strategy centers on high-impact innovation, trusted customer relationships, and a large commercial engine that can cross-sell instruments, consumables, and services. It also emphasizes R&D, geographic sales expansion, e-commerce, and operational productivity to deepen its position in scientific workflows and biopharma outsourcing.

High-impact innovationMedium term

New technologies and improved workflows help retain customers and win share in research and diagnostics.

Cross-selling through the commercial engineShort term

A broad portfolio lets the company sell multiple products into the same lab or biopharma account.

Expand biopharma servicesMedium term

Outsourced development, clinical research, and manufacturing deepen customer relationships and diversify revenue.

Productivity and cost efficiencyShort term

Operational efficiency supports competitiveness in a fragmented, price-sensitive lab market.

Geography

Q1/2026

Thermo Fisher operates globally and sells through direct sales, e-commerce, and distributors across North America, Europe, Asia-Pacific, and other international markets. Its manufacturing, service, and commercial footprint is broad, which supports local customer service but also exposes the company to cross-border supply chain, regulatory, and currency risks. The business depends on global demand from life sciences, diagnostics, and industrial end markets rather than a single country or region.

North America54 %
Europe28 %
Asia Pacific19 %

Share of the revenue the company reports by geography.

Risks

Thermo Fisher faces supply-chain and sourcing risk because some products depend on sole or limited suppliers and regulated materials. It also carries legal, quality, regulatory, and cybersecurity exposure, while its broad global footprint makes it sensitive to trade restrictions, geopolitical events, and currency movements. Goodwill and acquisition-related assets are also important because the company has grown through acquisitions and must support those values with future cash flows.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Supply chain concentration and supplier disruption1Regulatory, legal, and product quality exposure2Goodwill impairment risk3Geopolitical and trade restriction risk4Cybersecurity and technology disruption5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Supply chain concentration and supplier disruptionImpact: HighLikelihood: Medium

    Some materials and components come from sole or limited sources, making production vulnerable to interruptions.

    Exposure: Manufacturing and lab product supply chains

  2. Regulatory, legal, and product quality exposureImpact: HighLikelihood: Medium

    Diagnostics, instruments, and pharma services operate in regulated environments where failures can create claims or delays.

    Exposure: Clinical diagnostics and biopharma services

  3. Goodwill impairment riskImpact: HighLikelihood: Low

    Acquisition-driven growth leaves a large goodwill balance that depends on future cash flow assumptions.

    Exposure: Reporting units and acquired businesses

  4. Geopolitical and trade restriction riskImpact: MediumLikelihood: Medium

    International sourcing and sales can be disrupted by sanctions, tariffs, export controls, or war.

    Exposure: Global operations

  5. Cybersecurity and technology disruptionImpact: MediumLikelihood: Medium

    A large digital and commercial footprint increases exposure to ransomware and other cyber incidents.

    Exposure: Commercial systems and operations

Accounting

Judgemental items
Goodwill impairment

A large goodwill balance requires annual valuation testing and can be sensitive to discount rates and growth assumptions.

Impact: Could create non-cash impairment charges if expected cash flows weaken

Legal and product liability accruals

The company is contingently liable for certain legal proceedings and personal injury matters.

Impact: Can affect operating expense, liabilities, and cash outflows

Contingent consideration

Acquisition-related earn-outs and similar obligations must be remeasured over time.

Impact: Can create fair value gains or losses in earnings

Non-GAAP organic revenue growth

Management uses it to isolate underlying demand from acquisitions and currency effects.

Impact: Important for comparing reported growth to operational performance

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026